Adma Biologics Inc
ADMA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.85B
Close$
$7.07
8.9% downside
Current Fair Value
8.9% downsideOvervalued by 8.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.85 Billion |
|---|---|
| Enterprise Value | $1.92 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.62 |
| Beta | 0.82 |
| Outstanding Shares | 236,072,751 |
Return
| Return on Equity | 42.36% |
|---|---|
| Return on Assets | 24.86% |
| Return on Invested Capital | 36.24% |
Valuation & Multiples
| P/E Ratio | 11.39 |
|---|---|
| PEG | 16.64 |
| Price to Sales | 3.88 |
| Price to Book Ratio | 7.76 |
| Enterprise Value to Revenue | 3.76 |
| Enterprise Value to EBIT | 8.94 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.53 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$0.20
Average shareholder expectationRevenue Estimate
$142.70 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.19
Average shareholder expectationRevenue Estimate
$134.42 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3477▼ 27.31% |
|---|---|
| Total Calls | 6,445,900▲ 119.76% |
| Total Puts | 2,241,200▲ 23.08% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 88.89%▼ 3.46% |
|---|---|
| Total Invested | $1.91B▼ 52.40% |
| Investors Holding | 371▼ 1.00% |
ESG Score
No data